This is a working overview of purity testing, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-05 and is reviewed periodically as new material appears.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
acronym = an abbreviation pronounced as if it were a word, e.g., SARS = severe acute respiratory syndrome, pronounced to rhyme with cars initialism = an abbreviation pronounced wholly or partly using the names of its constituent letters, e.g., CD = compact disc, pronounced cee dee pseudo-blend = an abbreviation whose extra or omitted letters mean that it cannot stand as a true acronym, initialism, or portmanteau (a word formed by combining two or more words). (a) = acronym, e.g.: SARS – (a) severe acute respiratory syndrome (i) = initialism, e.g.: CD – (i) compact disc (p) = pseudo-blend, e.g.: UNIFEM – (p) United Nations Development Fund for Women (s) = symbol (none of the above, representing and pronounced as something else; for example: MHz – megahertz) Some terms are spoken as either acronym or initialism, e.g., VoIP, pronounced both as voyp and V-O-I-P. (Main list of acronyms)
Wastewater treatment Macrophytes have an essential role in some forms of wastewater treatment, most commonly in small scale sewage treatment using constructed wetlands or in polishing lagoons for larger schemes.
Scans conducted during the studies showed that Sharrock's brain exhibited a heightened connection between the conscious and sub-conscious parts of her brain, which may aid easier memory recall – in particular for events that took place earlier in life. In December 2017, a man named Joey DeGrandis was verified as having HSAM by James McGaugh and subsequently featured in an article in Time magazine. DeGrandis also reports having poor short-term memory, indicating that HSAM does not necessarily improve one's short-term memory abilities. A 63-year-old man, anonymised as "The Amazing Memory Man" (MM) was featured in a paper by Neuropsychology in March 2018, where it is reported that he "appreciates that his memory for personally experienced life events and general knowledge are both exceptional, whereas his imaging the future is only average" (after scoring 123 on Episodic, 123 on Semantic, 112 on Spatial, and 91 on Future remembering memory types, all with a mean of 100). In October 2018, it was reported that teenager Tyler Hickenbottom, who is an identical twin, had the condition, which allowed him to "remember every day of his life like it was yesterday". Tim Rogers, an American video game developer and journalist, claims to experience the condition in several of his published works. John Romero, a video game developer and co-founder of id Software, has often said he has hyperthymesia, including in his 2023 autobiography, Doom Guy: Life in First Person. In 2024, Emily Nash, an 18-year-old high school student with HSAM, was featured in a CTV W5 story.
=== Timeline of the struggle for professional equality in France === 1900: Law allowing women full access to the bar, including the right to plead. 1907: A law authorizes married women to freely dispose of their salary. Previously, all earnings went to their husbands. They are also now allowed to sit on labor tribunals. 1908: Law grants eight weeks of maternity leave, unpaid. 1920: Women can join a union without their husband's authorization. 1924: Women are allowed to take the baccalauréat exam (some had already done so in the past, notably Julie-Victoire Daubié, but from now on, secondary education is the same for both sexes, allowing more girls to aim for this diploma). 1928: Two-month fully paid maternity leave is granted in the civil service. 1938: Women's legal incapacity is lifted. They can attend university, pursue studies, and obtain an identity card or passport without their husband's permission (Renoult law). However, the husband remains the head of the household and can forbid his wife from working. 1942: Widowed women are allowed to work, even if their husbands were employed, provided this does not cause layoffs. 1944: Women are granted the right to vote. 1945: The concept of "women's wages" is abolished. The principle "equal pay for equal work" is written into the legislation. 1946: Women can become judges. 1965: Reform of matrimonial regimes: women can work and open a bank account without their husband's authorization and benefit from social advantages. 1967: Medical contraception is legalized by the Neuwirth law.
== Structures involved in clinical attachment loss == Clinical attachment loss refers to the apical migration and destruction of the tissues that secure the tooth within the periodontium. This process involves the coordinated breakdown of epithelial, connective tissue, and osseous components that collectively form the periodontal attachment apparatus.
Sources: en.wikipedia.org
==== Scoring systems ==== To better understand how severe cachexia is in each person, doctors use scoring systems like the Cachexia Staging Score and Cachexia Score. The Cachexia Staging Score (CSS) looks at weight loss, muscle function, appetite loss, and lab test results to categorize people into four stages: non-cachexia, pre-cachexia, cachexia, and refractory cachexia. Those in more advanced stages have less muscle mass, more frequent age-related muscle loss, worse symptoms, poorer quality of life, as well as shorter survival periods.
The convention elected a national committee of 33 members, with 22 seats for the majority caucus, 8 seats for Harrington's Coalition Caucus, 2 for the Debs caucus, and one for the "independent" Samuel H. Friedman. These minority caucuses all opposed the name change. The convention voted on and adopted proposals for its program by a two-one vote, with the majority caucus winning every vote.
==== 5.B Transmembrane 1-electron transfer carriers ==== 5.B.1 The Phagocyte (gp91phox) NADPH Oxidase Family 5.B.2 The Eukaryotic Cytochrome b561 (Cytb561) Family 5.B.3 The Geobacter Nanowire Electron Transfer (G-NET) Family 5.B.4 The Plant Photosystem I Supercomplex (PSI) Family 5.B.5 The Extracellular Metal Oxido-Reductase (EMOR) Family 5.B.6 The Transmembrane Epithelial Antigen Protein-3 Ferric Reductase (STEAP) Family 5.B.7 The YedZ (YedZ) Family 5.B.8 The Trans-Outer Membrane Electron Transfer Porin/Cytochrome Complex (ET-PCC) Family 5.B.9 The Porin-Cytochrome c (Cyc2) Family
*) The Bezirk Karl-Marx-Stadt was named Bezirk Chemnitz for a short period at both the beginning and end of the republic, corresponding with the renaming and reversal of the city Chemnitz. Between 10 May 1953 and 30 May 1990, both the city and Bezirk were named Karl-Marx-Stadt. **) East Berlin was not officially a Bezirk, but from 1961 was provided with the function of one.
=== Vaccination === By 2006, China has successfully immunised 11.1 million children living in the country's poorest provinces against hepatitis B according to the Chinese health ministry, and the Global Alliance for Vaccines and Immunization (GAVI). However, China still has a long way to go before immunisation levels reach a percentage able to limit the spread of hepatitis B. China's health minister, Gao Qiang told a Beijing press conference that the project, while effective, has covered only one third of all children born in China since the project began in 2002. This does not mean the rest of China's children went unvaccinated. However, even within the project's target area, over one million newborns went unvaccinated each year because of access issues; health-care costs, lack of birth attendants, and the remoteness of their birthplaces, such as herder's huts, mountain villages, and remote farms. Until 2005, when a law banning the practice was passed, parents were charged fees for the administration of the vaccine. Even though the GAVI alliance (whose partners include UNICEF and the WHO), and Chinese government were providing the vaccine and one-use needles free of charge, health-care workers charged fees that parents were unwilling or unable to pay. Based on a 1992 epidemiological survey, the disease burden of those who are chronically infected with hepatitis B in China is estimated to be at 120 million, one third of the overall burden (360 million) as estimated by the WHO. China's national target is to reach greater than 85% vaccination.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.